At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed May 14, 2026 at 06:59 ET
Biogen reported mixed Phase 2 CELIA results for diranersen in early Alzheimer's disease. The study missed its primary endpoint (dose response on CDR-SB) but showed slowing of cognitive decline in pre-specified analyses and robust tau reduction across doses. Biogen plans to advance to registrational development, creating a mixed outlook for the stock.
- Phase 2 CELIA study (n=416) of diranersen (BIIB080) in early Alzheimer's disease did not meet its primary endpoint of dose response on CDR-SB at Week 76.
- Pre-specified analyses showed slowing of clinical decline, particularly at the lowest dose (60 mg every 24 weeks).
- Robust reductions in CSF tau and tau PET across all doses, consistent with Phase 1b data.
- Safety profile generally consistent with prior studies; higher serious adverse events at highest dose.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access